Substituted dihydroisoquinolinone compounds

• US 10,570,121 B2
• Filed: 10/10/2018
• Issued: 02/25/2020
• Est. Priority Date: 06/17/2014
• Status: Active Grant

• Current Assignee: Pfizer Inc.
• Original Assignee: Pfizer Inc.
• Inventors: Collins, Michael Raymond, Kania, Robert Steven, Kumpf, Robert Arnold, Kung, Pei-Pei, Richter, Daniel Tyler, Sutton, Scott Channing, Wythes, Martin James
• Primary Examiner(s): Davis, Zinna Northington
• Application Number:
  US16/156,304
• Publication Number:
  US 20190040047A1
• Time in Patent Office: 503 Days
• Field of Search: None
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07B 2200/05 Isotopically modified compounds, e.g. labelled
• CPC Class Codes: C07B 59/002 Heterocyclic compounds
• CPC Class Codes: C07D 401/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 405/14 containing three or more hetero rings
• CPC Class Codes: C07D 409/14 containing three or more hetero rings
• CPC Class Codes: C07D 413/14 containing three or more hetero rings

Abstract

This invention relates to compounds of general formula (I)

• • in which R¹, R², R³, R⁴, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Claims

1. A compound of Formula (I-A):

2. The compound or salt of claim 1, wherein R³ is 3-12 membered heterocyclyl selected from the group consisting of oxetanyl, tetrahydrofuranyl and tetrahydropyranyl, each optionally substituted by one or more R⁷.

3. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

4. A method for the treatment of abnormal cell growth in a subject, comprising administering to the subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.